BridgeBio Oncology Therapeutics, Inc. Increase (Decrease) in Participation Liabilities
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Increase (Decrease) in Participation Liabilities of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes
us-gaap:IncreaseDecreaseInParticipationLiabilities · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in participation liabilities for the quarter ending 2026-06-30 was $0.00.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in participation liabilities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in participation liabilities for the quarter ending 2025-12-31 was $0.00.
- BridgeBio Oncology Therapeutics, Inc. increase (decrease) in participation liabilities for the quarter ending 2025-06-30 was $0.00.
| Period end | Increase (Decrease) in Participation Liabilities 3 month | Increase (Decrease) in Participation Liabilities 6 month | Increase (Decrease) in Participation Liabilities 9 month | Increase (Decrease) in Participation Liabilities 12 month | Increase (Decrease) in Participation Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | |||
| 2025-12-31 | $0.00 8-K · filed 2026-03-05 | $725.00K POS AM · filed 2026-04-30 | -$725.00K 8-K · filed 2026-03-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $725.00K 10-Q · filed 2026-08-11 | $725.00K derived: sum of 3 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $725.00K 10-Q · filed 2026-05-12 | $725.00K derived: sum of 2 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $0.00 8-K · filed 2026-03-05 | $564.00K POS AM · filed 2026-04-30 | -$564.00K 8-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |